Hyloris Pharmaceuticals SA (52U)

Overview

Hyloris Pharmaceuticals SA is a company dedicated to the development, manufacture, and delivery of pharmaceutical products designed to meet unmet medical needs, particularly in the realm of cardiovascular health among other major therapeutic areas. Having started its operations in 2012, the company has established its headquarters in Liège, Belgium. Hyloris Pharmaceuticals is focused on offering innovative solutions to various medical challenges, aiming to improve patient outcomes and enhance the quality of care. Through a combination of expertise in drug development and commitment to addressing gaps in healthcare, Hyloris Pharmaceuticals continues to expand its reach in the pharmaceutical industry.

Products and Services

Hyloris Pharmaceuticals SA offers an extensive range of products targeting different therapeutic areas, notably in cardiovascular health and pain management, as well as treatments for viral infections, cancer, and other conditions:

• Maxigesic IV: A non-opioid post-operative pain management solution that combines paracetamol and ibuprofen, offering an effective alternative for pain relief.
• Tranexamic acid RTU: An antifibrinolytic drug used to prevent the formation of blood clots, catering to patients in need of this specific treatment.
• Miconazole/Domiphen Bromide: A topical treatment targeting Recurrent Vulvovaginal Candidiasis, this synergistic combination aims to provide relief and treat this uncomfortable condition.
• AlenuraTM: Positioned as a first-line treatment for acute pain associated with interstitial cystitis/bladder pain syndrome, offering patients a novel therapeutic option.
• Plecoid Agent IV: Designed for the treatment of acute myeloid leukemia and small cell lung cancer, demonstrating the company's commitment to combating cancer through innovative treatments.
• Atomoxetine: An oral liquid formulation intended for patients with attention deficit hyperactivity disorder, providing a vital therapeutic option in the realm of mental health.
• HY-029: A liquid formulation of an antiviral drug to treat viral infections, showcasing Hyloris Pharmaceuticals' contributions to addressing the need for effective antiviral medications.
• HY-083: A nasal spray developed for the treatment of idiopathic rhinitis, offering a novel approach to managing this condition.
• HY-088: An oral liquid that addresses hypophosphatemia, further illustrating the company's broad approach to tackling various healthcare challenges.